Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - 21st Century Oncology Holdings, Inc. | a16-18681_110q.htm |
| EX-32.2 - EX-32.2 - 21st Century Oncology Holdings, Inc. | a16-18681_1ex32d2.htm |
| EX-32.1 - EX-32.1 - 21st Century Oncology Holdings, Inc. | a16-18681_1ex32d1.htm |
| EX-31.2 - EX-31.2 - 21st Century Oncology Holdings, Inc. | a16-18681_1ex31d2.htm |
| EX-31.1 - EX-31.1 - 21st Century Oncology Holdings, Inc. | a16-18681_1ex31d1.htm |
Exhibit 99.1
Supplemental Financial Information
21st Century Oncology, Inc. (21C), a subsidiary of the Company, has payment obligations under the senior secured credit facility, and Senior Notes that are guaranteed by the Company. The Company owns 100% of 21C and certain domestic subsidiaries of 21C, all of which are, directly or indirectly, 100% owned by 21C (the “Subsidiary Guarantors” and, collectively with the Company, the “Guarantors”). Such guarantees are full, unconditional and joint and several. The consolidated joint ventures, foreign subsidiaries and professional corporations of the Company are non-guarantors. The following supplemental financial information sets forth, on an unconsolidated basis, selected balance sheet accounts, revenues and adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) information.
21ST CENTURY ONCOLOGY HOLDINGS, INC.
Supplemental Financial Information
June 30, 2016
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Balance Sheets Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
As of June 30, 2016 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
Cash |
|
26,452 |
|
25,754 |
|
— |
|
52,206 |
|
|
Current assets (excluding cash) |
|
128,934 |
|
46,645 |
|
(13,447 |
) |
162,132 |
|
|
Long-term assets |
|
959,897 |
|
156,746 |
|
(226,141 |
) |
890,502 |
|
|
Total Assets |
|
1,115,283 |
|
229,145 |
|
(239,588 |
) |
1,104,840 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
Current portion of debt |
|
1,099,997 |
|
2,455 |
|
— |
|
1,102,452 |
|
|
Current liabilities (excluding debt) |
|
145,200 |
|
18,512 |
|
(13,447 |
) |
150,265 |
|
|
Long-term debt, less current portion |
|
20,079 |
|
4,820 |
|
— |
|
24,899 |
|
|
Long-term liabilities (excluding debt) |
|
178,462 |
|
43,408 |
|
(108,831 |
) |
113,039 |
|
|
Total Liabilities |
|
1,443,738 |
|
69,195 |
|
(122,278 |
) |
1,390,655 |
|
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Income Statement Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
For the Six Months Ended June 30, 2016 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
420,674 |
|
137,613 |
|
(29,606 |
) |
528,681 |
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
70,254 |
|
16,158 |
|
(6,873 |
) |
79,539 |
|
|
EBITDA Adjustments: |
|
|
|
|
|
|
|
|
|
|
Intercompany equity investments |
|
(6,873 |
) |
— |
|
6,873 |
|
— |
|
|
Net income attributable to noncontrolling interest |
|
— |
|
3,112 |
|
— |
|
3,112 |
|
|
Noncontrolling interest cash distributions |
|
— |
|
(1,407 |
) |
— |
|
(1,407 |
) |
|
Gain on the contribution of a radiation facility to a joint venture |
|
(12,629 |
) |
— |
|
— |
|
(12,629 |
) |
|
Gain on BP settlement |
|
(517 |
) |
— |
|
— |
|
(517 |
) |
|
Impairment loss |
|
1,825 |
|
— |
|
— |
|
1,825 |
|
|
Fair value adjustment of earn-out liabilities |
|
1 |
|
— |
|
— |
|
1 |
|
|
Fair value adjustment of embedded derivatives and other financial instruments |
|
(12,790 |
) |
— |
|
— |
|
(12,790 |
) |
|
Other expenses |
|
3,659 |
|
76 |
|
— |
|
3,735 |
|
|
Non-cash expenses |
|
1,496 |
|
137 |
|
— |
|
1,633 |
|
|
Sale-lease back adjustments |
|
(582 |
) |
— |
|
— |
|
(582 |
) |
|
Acquisition-related costs |
|
959 |
|
31 |
|
— |
|
990 |
|
|
Litigation matters |
|
1,252 |
|
— |
|
— |
|
1,252 |
|
|
Expenses associated with debt/waiver amendments and restatement of previously issued financial statements |
|
8,181 |
|
— |
|
— |
|
8,181 |
|
|
Sub-total |
|
54,236 |
|
18,107 |
|
— |
|
72,343 |
|
|
Allocated share of Non-Guarantor EBITDA to Guarantor |
|
12,403 |
|
(12,403 |
) |
— |
|
— |
|
|
Pro-Forma Adjusted EBITDA |
|
66,639 |
|
5,704 |
|
— |
|
72,343 |
|
21ST CENTURY ONCOLOGY HOLDINGS, INC.
Supplemental Financial Information
June 30, 2015
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Balance Sheets Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
As of December 31, 2015 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
Cash |
|
48,336 |
|
16,875 |
|
— |
|
65,211 |
|
|
Current assets (excluding cash) |
|
121,775 |
|
44,283 |
|
(9,992 |
) |
156,066 |
|
|
Long-term assets |
|
895,264 |
|
170,023 |
|
(182,703 |
) |
882,584 |
|
|
Total Assets |
|
1,065,375 |
|
231,181 |
|
(192,695 |
) |
1,103,861 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
Current portion of debt |
|
1,020,343 |
|
3,534 |
|
— |
|
1,023,877 |
|
|
Current liabilities (excluding debt) |
|
169,946 |
|
28,556 |
|
(9,912 |
) |
188,590 |
|
|
Long-term debt, less current portion |
|
43,728 |
|
5,505 |
|
— |
|
49,233 |
|
|
Long-term liabilities (excluding debt) |
|
138,867 |
|
44,104 |
|
(74,927 |
) |
108,044 |
|
|
Total Liabilities |
|
1,372,884 |
|
81,699 |
|
(84,839 |
) |
1,369,744 |
|
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Income Statement Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
For the Six Months Ended June 30, 2015 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
355,806 |
|
240,094 |
|
( 42,054 |
) |
553,846 |
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
5,179 |
|
23,794 |
|
(12,930 |
) |
16,043 |
|
|
EBITDA Adjustments: |
|
|
|
|
|
|
|
|
|
|
Intercompany equity investments |
|
(12,930 |
) |
— |
|
12,930 |
|
— |
|
|
Net income attributable to noncontrolling interest |
|
— |
|
4,080 |
|
— |
|
4,080 |
|
|
Noncontrolling interest cash distributions |
|
— |
|
(2,022 |
) |
— |
|
(2,022 |
) |
|
Early extinguishment of debt |
|
37,390 |
|
— |
|
— |
|
37,390 |
|
|
Fair value adjustment of earn-out liabilities |
|
(1,644 |
) |
1,114 |
|
— |
|
(530 |
) |
|
Fair value adjustment of embedded derivatives and other financial instruments |
|
7,135 |
|
— |
|
— |
|
7,135 |
|
|
Other expenses |
|
3,821 |
|
124 |
|
— |
|
3,945 |
|
|
Non-cash expenses |
|
2,111 |
|
238 |
|
— |
|
2,349 |
|
|
Sale-lease back adjustments |
|
(764 |
) |
— |
|
— |
|
(764 |
) |
|
Acquisition-related costs |
|
2,230 |
|
149 |
|
— |
|
2,379 |
|
|
Litigation matters |
|
18,519 |
|
— |
|
— |
|
18,519 |
|
|
Sub-total |
|
61,047 |
|
27,477 |
|
— |
|
88,524 |
|
|
Allocated share of Non-Guarantor EBITDA to Guarantor |
|
18,866 |
|
(18,866 |
) |
— |
|
— |
|
|
Pro-Forma Adjusted EBITDA |
|
79,913 |
|
8,611 |
|
— |
|
88,524 |
|
21ST CENTURY ONCOLOGY HOLDINGS, INC.
Supplemental Financial Information
June 30, 2016
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Income Statement Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
For the Three Months Ended June 30, 2016 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
203,925 |
|
69,695 |
|
(15,237 |
) |
258,383 |
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
25,909 |
|
8,115 |
|
(3,308 |
) |
30,716 |
|
|
EBITDA Adjustments: |
|
|
|
|
|
|
|
|
|
|
Intercompany equity investments |
|
(3,308 |
) |
— |
|
3,308 |
|
— |
|
|
Net income attributable to noncontrolling interest |
|
— |
|
1,316 |
|
— |
|
1,316 |
|
|
Noncontrolling interest cash distributions |
|
— |
|
(1,193 |
) |
— |
|
(1,193 |
) |
|
Gain on BP settlement |
|
(517 |
) |
— |
|
— |
|
(517 |
) |
|
Impairment loss |
|
1,825 |
|
— |
|
— |
|
1,825 |
|
|
Fair value adjustment of embedded derivatives and other financial instruments |
|
(10,255 |
) |
— |
|
— |
|
(10,255 |
) |
|
Other expenses |
|
2,189 |
|
43 |
|
— |
|
2,232 |
|
|
Non-cash expenses |
|
739 |
|
54 |
|
— |
|
793 |
|
|
Sale-lease back adjustments |
|
(292 |
) |
— |
|
— |
|
(292 |
) |
|
Acquisition-related costs |
|
336 |
|
22 |
|
— |
|
358 |
|
|
Litigation matters |
|
386 |
|
— |
|
— |
|
386 |
|
|
Expenses associated with debt/waiver amendments and restatement of previously issued financial statements |
|
7,981 |
|
— |
|
— |
|
7,981 |
|
|
Sub-total |
|
24,993 |
|
8,357 |
|
— |
|
33,350 |
|
|
Allocated share of Non-Guarantor EBITDA to Guarantor |
|
5,725 |
|
(5,725 |
) |
— |
|
— |
|
|
Pro-Forma Adjusted EBITDA |
|
30,718 |
|
2,632 |
|
— |
|
33,350 |
|
21ST CENTURY ONCOLOGY HOLDINGS, INC.
Supplemental Financial Information
June 30, 2015
|
|
|
Parent |
|
|
|
|
|
|
|
|
Selected Income Statement Accounts |
|
Issuer & |
|
|
|
|
|
|
|
|
For the Three Months Ended June 30, 2015 |
|
Guarantor |
|
Non Guarantor |
|
Eliminations |
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Revenues |
|
178,423 |
|
121,868 |
|
(22,078 |
) |
278,213 |
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
(17,499 |
) |
12,073 |
|
(11,616 |
) |
(17,042 |
) |
|
EBITDA Adjustments: |
|
|
|
|
|
|
|
|
|
|
Intercompany equity investments |
|
(11,616 |
) |
— |
|
11,616 |
|
— |
|
|
Net income attributable to noncontrolling interest |
|
— |
|
1,821 |
|
— |
|
1,821 |
|
|
Noncontrolling interest cash distributions |
|
— |
|
(1,058 |
) |
— |
|
(1,058 |
) |
|
Early extinguishment of debt |
|
37,390 |
|
— |
|
— |
|
37,390 |
|
|
Fair value adjustment of earn-out liabilities |
|
(1,876 |
) |
886 |
|
— |
|
(990 |
) |
|
Fair value adjustment of embedded derivatives and other financial instruments |
|
5,442 |
|
— |
|
— |
|
5,442 |
|
|
Other expenses |
|
1,937 |
|
71 |
|
— |
|
2,008 |
|
|
Non-cash expenses |
|
1,303 |
|
35 |
|
— |
|
1,338 |
|
|
Sale-lease back adjustments |
|
(315 |
) |
— |
|
— |
|
(315 |
) |
|
Acquisition-related costs |
|
979 |
|
90 |
|
— |
|
1,069 |
|
|
Litigation matters |
|
16,578 |
|
— |
|
— |
|
16,578 |
|
|
Sub-total |
|
32,323 |
|
13,918 |
|
— |
|
46,241 |
|
|
Allocated share of Non-Guarantor EBITDA to Guarantor |
|
9,556 |
|
(9,556 |
) |
— |
|
— |
|
|
Pro-Forma Adjusted EBITDA |
|
41,879 |
|
4,362 |
|
— |
|
46,241 |
|